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NEONATAL ABSTINENCE SYNDROME: A RETROSPECTIVE REVIEW OF
CLONIDINE AS AN ADJUNCT TO OPIOD TREATMENT. Joanna J. Schatz
(Sponsored by Matthew R. Grossman). Department of Pediatrics, Yale University,
School of Medicine, New Haven, CT.
This was a retrospective medical record review of treatment for neonatal abstinence
syndrome (NAS) due to in utero exposure to opioids. The purpose of our study was to
determine if there was a difference in the duration of treatment between infants who
received morphine alone compared to infants who were treated with both morphine and
clonidine. We hypothesized that there would be a decrease in the duration of treatment in
infants treated with both morphine and clonidine compared to infants treated with
morphine alone. The primary outcome was duration of treatment for NAS. Medical
records of infants born at Yale New Haven Hospital (YNHH) between January 2003 and
December 2009 were reviewed. 117 infants met the inclusion criteria. 59 were treated
with morphine, and 58 were treated with morphine and clonidine. The mean length of
stay of infants treated with morphine and clonidine was significantly shorter than the
mean length of stay of infants treated with morphine alone, 19.57 days (SD 9.896) and
25.14 days (SD 12.738) respectively (p<0.05). Both groups were similar with regard to
infant demographic factors, and there was no significant difference in the maximum dose
of diluted morphine in either treatment group (P=0.410). These results suggest that
infants treated with morphine and clonidine for NAS have decreased lengths of
pharmacotherapy compared to infants treated with morphine alone.
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Introduction
Illicit drug abuse and prescription drug use during pregnancy results in neonatal
exposure potentially leading to physical dependence of the infant after birth. Moreover,
illicit drug use among women of childrearing age is not an uncommon problem. National
estimates from the NSDUH combined data for 2007 and 2008 found that 5.1 percent of
pregnant women ages 15 to 44 years had used illicit drugs in the past month, which is
similar to the rates from 2004-2005 (4.0 percent) and 2003-2004 (4.6 percent). Although
this is a conservative estimate that uses the prevalence of illicit drug use at a specific
point any time during a pregnancy, it illustrates that in utero exposure to illicit substances
is both a significant clinical and a significant social problem. (1-3) In the United States
an estimated 7000 infants are born every year having been exposed in utero to opioids.
(4) Of these infants, 55-94 percent may subsequently develop signs and symptoms of
opioid withdrawal know as neonatal abstinence syndrome (NAS). (5-8) NAS is
characterized by a constellation of central nervous system (CNS), gastrointestinal (GI),
and autonomic symptoms that neonates exposed to opioids in utero are at risk of
developing. NAS is a complex clinical syndrome that varies widely in presentation and
clinical course. The complexity and variability of NAS, as well as the population that is
at risk for developing NAS, make it a difficult entity to study.
Clinical manifestations of NAS include: neurologic hyperexcitability with highpitched crying, yawning, sneezing, skin excoriation, tremors, irritability, disruption of the
sleep-wake cycle, hypertonicity, hyperreflexia, and seizures; enteric symptoms with poor
feeding, vomiting, diarrhea, increased sucking and dehydration; and autonomic
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dysregulation with increased sweating, increased temperature/fever, nasal congestion,
tachypnea, and mottling of the skin. These symptoms usually develop within the first 72
hours following birth but can be delayed for several days and up to four weeks. In utero
exposure to heroin generally presents within 48 hours and methadone within 48-72 hours.
(9, 10)
Assessment and treatment of this complex clinical syndrome varies widely across
the country and throughout the world. (11, 12) This variability persists in part because
the increasing body of literature regarding the characterization and management of NAS
has yielded conflicting results, and the studies are often limited by both design as well as
by the study population. There have been studies that have attempted to systematically
review the literature and offer clarification and guidance to physicians treating this
complex clinical syndrome. The guidelines set forth by the American Academy of
Pediatrics (AAP) Committee on Drugs in 1998 for the management of neonatal drug
withdrawal made the following recommendations:
1. Screening for maternal substance abuse using multiple methods (i.e. history,
toxicology screening etc.)
2. Drug withdrawal should be considered in infants with signs and symptoms
consistent with the diagnosis, although other diagnoses in the differential
should be evaluated and treated if present.
3. Withdrawal should be scored using an appropriate scoring tool which should
be used to help govern treatment decisions in a more objective and
quantitative way.
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4. Withdrawal-associated seizures should be treated, and other possible
etiologies should be ruled out.
5. Vomiting, diarrhea, dehydration and poor weight gain are indications for
treatment even in the absence of a high withdrawal score.
6. The pharmacologic treatment for withdrawal should match the type of agent
causing the withdrawal (i.e. opiates for opiate withdrawal).
7. Severity of withdrawal has not been proven to be associated with differences
in long term outcome after intrauterine drug exposure. Additionally,
treatment for neonatal drug withdrawal may not alter long-term outcome.
8. Naloxone is contraindicated in infants born to mothers who are known to be
opioid-dependent. (13)
Although there are guidelines such as the aforementioned AAP guidelines,
subsequent studies have shown that having guidelines does not directly translate into
incorporating those guidelines in every day clinical practice. One study done by Sakar et
al. surveyed neonatal intensive care units (NICU) across the country. They found that
only about half of the NICUs had a written policy governing the management of NAS.
Additionally, 65 of the 75 sites that responded to the survey reported using some sort of
scoring tool, such as the Finnegan Score, to quantify the severity of withdrawal, although
ten sites reported not using a scoring tool at all. Despite using a scoring tool, only 70
percent of sites, 53 respondents, reported consistently using a scoring tool to govern
treatment (i.e. using the scores to dictate when treatment was initiated, as well as when
medication doses were increased or weaned). Eighty-three percent of the sites that
responded to the survey reported routinely obtaining either urine or meconium for

4
toxicology screening before starting pharmacologic intervention for NAS. Finally, 63
percent of respondents, 47 sites, used opioids as the first line treatment for opioid
withdrawal. (11) Examination of the AAP recommendations and the results of the study
done by Sakar et al. highlights the difficulty of adopting and implementing evidencebased clinical practice guidelines. Not only has passive dissemination of information
been found to be largely ineffective in promoting implementation of research findings,
but the data with regards to NAS is vast and varied which further complicates
implementation of evidence-based practices. (14)
The research on NAS is varied in part because it is an entity that is difficult to
study due to the heterogeneity of the clinical presentation and course, as well as the
heterogeneity of the population in which the syndrome occurs. NAS is manifested
clinically as a broad spectrum of presentations influenced by maternal, fetal and
environmental factors. These factors include but are not limited to the type and dosage of
drug(s), timing and amount of last maternal use of the drug(s), as well as maternal and
infant metabolism and excretion of the drug(s). (8, 11) In addition to multiple factors
playing a role in the manifestation of NAS, the dynamic nature of maternal-fetal dyad
throughout pregnancy with continuous morphological and physiological changes not only
in the mother and fetus, but also in the placenta, further complicates matters. Although
one of the key elements in understanding the dynamic presentation of NAS is
understanding the pharmacologic properties of a drug in the maternal-fetal dyad
including the mechanism action, the kinetics, and the dynamics, studies that aim to
elucidate the effect of prenatal exposure are limited by both ethical as well as technical
factors. (15)
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Defining and understanding neonatal abstinence syndrome becomes further
complicated by the myriad of drugs an infant may have been exposed to in utero. Often
maternal use of opioids such as heroin, methadone, morphine or dilaudid is not
independent of maternal use of other substances including but not limited to tobacco,
alcohol, barbiturates and benzodiazepines. (16-18) One study that examined the drug use
patterns of pregnant women in two inner city sites found that cocaine use is associated
with an increase in tobacco, alcohol and marijuana use. (16) Although NAS is typically
associated with prenatal opioid exposure and much of the research on NAS focuses on
heroin and methadone, in every day clinical practice, infants with signs and symptoms of
withdrawal will often have been exposed to multiple illicit substances at various points
during gestation. Additionally, obtaining a reliable history of in utero exposure is
incredibly difficult. Maternal self-report is often plagued by under-reporting and can be
unreliable, thus it has a low sensitivity and high false negative rates. Toxicology studies
done on urine at the time of delivery or meconium only capture the very recent history of
substance use, although they are more sensitive and specific as well as cost effective.
Finally, hair analysis has the benefit of giving a longitudinal view of substance exposure
in addition to having a high sensitivity. However, hair analysis is not only costly, but it
can also have false-positive results for passive exposure (19, 20)
Methadone maintenance programs have become the standard of care for opioiddependent pregnant women and have, in part, alleviated some of the polysubstance use
and other psychosocial issues associated with opioid-dependence during pregnancy.
These types of programs include comprehensive services that increase access to and
usage of prenatal care as well as psychosocial support services. This, in turn, has led to
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increased stability of lifestyle, reduced risk-taking behavior, as well as reduction in the
number of preterm births and infants with intrauterine growth restriction. (21, 22)
The evidence regarding the prevalence of continued heroin use and concurrent
polysubstance use of pregnant women in methadone maintenance programs is consistent
with the evidence in other areas of research on NAS: it is varied. There is evidence to
support that some opioid-dependent pregnant women treated in methadone maintenance
programs continue to use heroin as well as other illicit substances which ultimately
impacts the postnatal outcomes of their infants.
One study done by Leifer et al. looked specifically at the extent of polysubstance
abuse among female pregnant patients in a methadone maintenance program, the Family
Center Program in Philadelphia. The study population had been in the program for at
least four months. Researchers collected urine samples upon admission to the program,
once a week at random, upon admission to the hospital for delivery, and at any point that
a subject missed one or more consecutive doses of methadone. Upon admission to the
program, subjects were stabilized on a methadone dose that prevented withdrawal
symptoms. Within their study population of 100 subjects, 98 percent were multi-drug
users. This was consistent with a study done by Chambers in 1972 that found that 97
percent of methadone-maintained patients at Philadelphia General Hospital were multidrug users. (23) They reported that 74 percent of their patients continued to use heroin
despite methadone maintenance treatment and only rare physician refusals of patient’s
requests to increase the methadone dose. (24) Harper et al. reported that women in the
Family and Maternal Care Program (FMCP) at the State University of New York
Downstate Medical Center enrolled 51 women between the ages of 21 and 25. All of
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these women were addicted to heroin when enrolled in the study and started on
methadone detoxification therapy. Urine toxicology studies showed that 23 of 51 women
used no other illicit substances after joining the FMCP, 27 women used heroin at least
once after entering the program, eight of the 27 women used barbiturates at least once,
and five women had a positive test for either barbiturates alone or other drugs. Of note,
the incidence of heroin use decreased markedly the longer a woman remained in the
program. (6) The implications of these studies are that polysubstance use during
pregnancy continues to be an important issue in the evaluation and treatment of NAS
despite advances made by methadone maintenance programs.
As stated previously, there is a large and heterogeneous body of literature on the
treatment of NAS. The main goals of treatment are to ameliorate symptoms of NAS,
promote neuromaturation and self-organization of the infant, and to reduce morbidity.
(28) The first line of treatment is supportive care which includes but is not limited to
holding, swaddling, minimal stimulation, and rooming-in. (13, 17, 18, 25-28)
Supportive care may be adequate for mild withdrawal, but infants with NAS often
require treatment beyond supportive care with opiates and/or sedatives, and should be
assessed with the aid of a NAS scoring tool such as the Finnegan Neonatal Abstinence
Scoring System, Lipsitz Tool, or Neonatal Withdrawal Inventory. (30-33) In one study
done by Zelson et al., 68.7 percent of infants that manifested signs of withdrawal
required pharmacologic intervention. (9) In another study done by van Baar et al., 80
percent of infants born to drug dependent mothers required pharmacologic intervention.
(29) Pharmacologic intervention should aim to quell hyperactivity and autonomic
instability and promote feeding, weight gain and normal sleep patterns. The choice of
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pharmacotherapy is less straightforward, and many different agents have been used over
the years, including several different opioids (methadone, morphine, diluted tincture of
opium, and paregoric), clonidine, chloral hydrate, chlorpromazine, diazepam, and
phenobarbitone. (34)
There have been two recent Cochrane reviews that examined pharmacologic
treatment, specifically sedatives and opiates, for opiate withdrawal in newborn infants.
(35, 36) One review aimed to assess the safety and efficacy of sedative treatment for
NAS compared to non-opiate control. It also sought to determine the safest and most
effective sedative for the treatment of NAS. The review included six studies with a total
of 305 subjects. Based on their review, Osborn et al. concluded that trials of sedatives
have generally been of poor quality. When a sedative is needed for the treatment of
NAS, the preferred agent is phenobarbitone. Even though phenobarbitone alone has not
been shown to reduce treatment failure, when it is compared to supportive treatment, it
may reduce the daily duration of supportive care needed, and it may also reduce the
severity of withdrawal in infants who are also treated with an opioid. (35) The second
review sought to assess the efficacy of opioid treatment for NAS and included seven
studies with 585 total subjects. Based on this review, Osborn et al. concluded that
opioids, when compared to supportive care, appear to reduce the time it takes an infant to
regain birth weight, reduce the duration of supportive care, but increase the duration of
hospital stay. Also, opioids, when compared to sedatives such as phenobarbitone, may
reduce the incidence of seizure and duration of treatment, although no overall effect was
found on treatment failure rate. In comparison to diazepam, opioids do reduce the
incidence of treatment failure. (36)
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A third review by Johnson et al. also supports the findings of the Cochrane review
as well as the AAP guidelines that opioids should be used as the first line treatment for
infants exposed to opioids in utero who subsequently develop NAS. (34) These findings
are consistent with what one might expect when examining at the pharmacologic actions
of opioids on the central nervous system. Opioids act on the opiate receptors, mu, delta,
and kappa, throughout the brain and more specifically in one of the brain’s major
noradrenergic centers, the locus ceruleus, a nucleus in the dorsal pons that projects
diffusely to the forebrain, brainstem and spinal cord. On a molecular level, binding to the
receptors of these transmembrane proteins leads to the activation of second messengers
within the cell and decreases the activity of adenylate cyclase leading to the reduction of
cyclic AMP (cAMP). (37, 38) The reduction of cAMP is inhibitory and subsequently
leads to potassium efflux and calcium influx into the noradrenergic neurons and
decreased norepinephrine release. (39) Chronic exposure to opioids leads to increased
release of norepinephrine to overcome the inhibitory effects on noradrenergic neurons.
Abrupt discontinuation of opioid exposure, as is the case with infants transitioning to
extrauterine life, leads to the loss of this inhibitory effect and to significant increases in
noradrenergic activity. Increase in noradrenergic activity in the brain is manifested
clinically as symptoms of withdrawal. (40) Thus, by administering opioids, this
noradrenergic hyperactivity is reduced, leading to amelioration of withdrawal symptoms.
(34)
Clonidine hydrochloride has also been suggested as a potential treatment for NAS
in the literature. It is an α-2-adrenergic receptor agonist often used for its
antihypertensive properties. (41) In the central nervous system, it acts presynaptically in
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the locus ceruleus on α-2-adrenergic receptors decreasing catecholamine, specifically
norepinephrine, release. (34, 41, 42) Thus, clonidine acts on α-2-mediated inhibition
rather than opioid-mediated inhibition of brain noradrenergic activity with similar
reductions in withdrawal symptoms. Although the action of clonidine suppresses the
symptoms associated with opioid withdrawal, it has limitations as a single agent,
especially due to its side effects of hypotension and bradycardia. (43)
Studies in older children and adults have shown clonidine to be efficacious in the
treatment of opioid withdrawal. (43-48) In one study done by Gold et al. clonidine was
found to produce a rapid and statistically significant decrease in opiate withdrawal signs
and symptoms in ten adult patients who underwent abrupt discontinuation of methadone
in an inpatient setting. (44) A double-blind, placebo-controlled, cross-over trial done by
Gold et al. found that clonidine eliminated signs and symptoms of opiate withdrawal in
eleven patients in a hospital setting for a period of 240-360 minutes. (45)
Although there is clear evidence to support the use of clonidine for the treatment
of opioid withdrawal in older children and adults, the data on the use of clonidine in
infants with NAS has been limited to only a few studies. (35, 49-51) A pilot study done
by Hoder et al. reported that clonidine effectively ameliorated the symptoms of neonatal
narcotic withdrawal in six out of seven infants. They also did a retrospective review of
13 infants treated with phenobarbitone and found that the length of treatment in the
clonidine group was significantly less than that of the phenobarbitone group, six to 27
days with a mean of 13 days and 15 to 55 days with a mean of 27 days respectively (t =
2.93, df = 18, p < 0.05). Even though the few studies of clonidine seem to indicate that
clonidine is a reasonable and useful treatment for NAS, larger reviews have found that
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there is insufficient data to support the use of clonidine for NAS. (13, 34-36) However,
the reviews that cited insufficient data for the use of clonidine for the treatment of NAS
were all published prior to the publication of a study done by Agthe et al. which clearly
indicated that clonidine in addition to opioid therapy is more efficacious than opioid
therapy alone (35, 49-51)
The study done by Agthe et al. is the largest prospective double-blind,
randomized trial of any kind in NAS. It is also the first randomized, controlled trial of
clonidine. It enrolled 80 infants with intrauterine exposure to either heroin or methadone
and NAS as defined by two consecutive modified Finnegan scores of ≥ 9, and followed
them throughout their hospital course until discharge. Infants were randomly assigned to
receive either oral clonidine or placebo in addition to treatment with diluted tincture of
opium. The primary outcome of the study was duration of treatment with opioid therapy.
(51)
They found that the group of infants treated with both diluted tincture of opium
and clonidine had a significantly shorter duration of treatment (27 percent shorter) as
compared to those who received diluted tincture of opium and placebo, median of 11
days and 15 days respectively. In addition to a longer duration of treatment, the placebo
group required higher doses of opioids in 40 percent of infants as compared to the
clonidine group which required higher doses of opioids in only 20 percent of infants.
Additionally, there were no treatment failures in the clonidine group, and treatment
failures occurred in 12.5 percent of the placebo group. In the clonidine group, however,
seven infants required recommencement of opioid therapy after initial discontinuation,
whereas none of the infants in the placebo group required opioid therapy to be restarted
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after discontinuation. Despite seven infants requiring recommencement of opioid
therapy, the duration of treatment was still significantly shorter in the clonidine group as
compared to placebo. In addition, neither group experienced adverse cardiovascular
outcomes including hypertension, hypotension, bradycardia or oxygen desaturations. (51)
Illicit drug use during pregnancy has been and remains an important issue in the
United States and throughout the world. (1-3) Historically, the characterization of
withdrawal in and treatment of infants exposed to opioids and other illicit substances in
utero has been challenging. Furthermore, there has been no clear consensus on the
optimal treatment regimen for this population, and the vast majority of studies are limited
by either study design, study population or both. Although organizations have attempted
to clarify this complex entity, recommendations and guidelines do not directly translate
into clinical practice and further clarification is needed. (11-14) Recommendations
suggest the use of opioids for opioid detoxification with the addition of sedatives if
additional intervention is needed. (13, 35, 36)
More recent reviews and studies have suggested the addition of an α-2-adrenergic
receptor agonist such as clonidine, which has clearly been shown to be efficacious in the
treatment of opioid withdrawal in older children and adults, may also be efficacious in
the treatment of infants with NAS. (43-47) It has been shown to reduce duration of
treatment as well as reduce the amount of opioid required to ameliorate the symptoms of
NAS. (49-51) The promising results of a small number of trials looking at clonidine as a
potential pharmacologic intervention for NAS indicate the need for additional studies to
corroborate and further characterize the potential benefits as well as long-term safety of
clonidine.
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Purpose
The purpose of this study was to look retrospectively at the medical records of
infants treated postnatally for neonatal abstinence syndrome at Yale New Haven Hospital
(YNHH) to determine if there was a difference in the duration of treatment between
infants who received diluted oral morphine sulfate alone compared to those who were
treated with both diluted oral morphine sulfate and diluted oral clonidine hydrochloride.
We hypothesized that there would in fact be a decrease in length of hospital stay in those
infants treated with both morphine and clonidine compared to those treated with
morphine alone. The primary outcome of this study was duration of treatment, which
was defined as the total number of days an infant received morphine with or without
clonidine for the treatment of NAS. Additionally, this study examined factors that could
potentially influence duration of treatment in infants with NAS such breastfeeding,
gestational age, birth weight, gender, Apgar scores, mode of delivery, and attending
physician.
Methods
A retrospective review of medical records was undertaken. The study was
reviewed and approved by the Yale Human Investigation Committee. Records of infants
born at Yale New Haven Hospital (YNHH) between January 2003 and December 2009
were identified using CPT codes for the diagnosis of NAS. Data was obtained by
thorough manual review by the investigator of both hardcopy paper medical records as
well as electronic medical records. The data collected included birth, admission and
discharge dates, gestational age, birth weight, gender, race, mode of delivery, Apgar
scores at one and five minutes, maximum dose of medication required to control
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symptoms of NAS, results of toxicology screening tests, history of intrauterine exposure
to illicit substances when available, and attending physician.

Criteria for inclusion in the study were:
•

Diagnosis of neonatal abstinence syndrome

•

Gestational Age ≥ 36 weeks

•

Treated at YNHH between January 2003 to December 2009

•

In utero exposure to opioids as determined by maternal history, toxicology or
infant toxicology

•

Symptoms of NAS requiring pharmacologic intervention

Diagnosis of NAS was determined initially by CPT code and subsequently by
review of the medical record. Gestational age was determined by medical record review.
In utero exposure to opioids was confirmed by toxicology results when available and
otherwise maternal history as recorded in the infant’s medical record was used.
Symptoms of NAS requiring pharmacologic intervention were determined by three
consecutive modified Finnegan scores with a total score of ≥ 24 over a period of 24 hours
as assessed by nursing staff every eight hours and subsequent initiation of treatment per
report in the medical record.

Criteria for exclusion from the study were:
•

Transferred to another facility during treatment

•

Diagnosis of iatrogenic NAS due to postnatal exposure to opioids
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•

Major concomitant medical illness i.e. sepsis, congenital anomalies, prematurity <
36 weeks, and the presence of seizures as part of the infant’s presenting symptom
complex

The standard treatment protocol for NAS at YNHH prior to 2006 was to monitor
infants at risk of developing NAS every eight hours for a total of three assessments in a
24 hour period of time (day, evening and night) using a modified Finnegan scoring
algorithm which includes scoring of withdrawal symptoms in three major areas, central
nervous system disturbances, metabolic/vasomotor/respiratory disturbances, and
gastrointestinal disturbances (Appendix A). Pharmacologic intervention with diluted oral
morphine sulfate was initiated when the total withdrawal score was 24 or greater over a
24 hour period of time. The starting dose of diluted oral morphine sulfate was 0.08-0.12
mg/kg/dose every four hours or the total 24 hour dose could be divided into every three
hour dosing if the infant was receiving feedings that frequently. This dose was increased
by 0.04 mg/dose every eight hours until signs of withdrawal were controlled (i.e. a score
less than ten over an eight hour period of time) or until a maximum dose of 0.4 mg/dose.
After signs of withdrawal were controlled for two to three days, infants were weaned by
ten percent decrements of the maximum dose of morphine sulfate every one to three days
with a goal of maintaining withdrawal scores less than ten over a 24 hour period of time.
Diluted oral morphine sulfate was discontinued when the dose had been weaned to 0.06
mg/dose. (See Figure 1)
The standard treatment protocol for NAS from 2006 to December 2009 was to
assess infants at risk of developing NAS every eight hours using the modified Finnegan
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algorithm and initiate pharmacologic intervention with both diluted oral morphine sulfate
and oral clonidine when the total withdrawal score was 24 or greater over 24 hours. The
starting dose of diluted oral morphine sulfate was 0.08-0.12 mg/kg/dose every three to
four hours depending on the feeding schedule. The morphine dose was increased by 20
percent of the initial dose every eight hours until the signs of withdrawal were controlled
with a withdrawal score less than ten over eight hours or a maximum dose of 0.2
mg/kg/dose was reached. Oral clonidine was administered at a dose of 1 mcg/kg/dose
every four hours or 0.75 mcg/kg/dose every three hours based on the infant’s feeding
schedule. If the maximum dose of morphine was reached, clonidine could be increased
by 25 percent to a maximum of 2 mcg/kg/dose every four hours or 1.5 mcg/kg/dose every
three hours.
After signs of withdrawal were controlled for two days with withdrawal scores
less than ten over each eight hour period of assessment, weaning of morphine by ten
percent of the maximum dose was begun. If there were two scores of ten or greater in a
24 hour period of time, consideration was given to increasing the morphine dose to the
last stable dose and extending the weaning interval back to two days. Diluted oral
morphine could be discontinued when the dose had been weaned to 0.06 mg/dose.
Twenty-four hours after the discontinuation of morphine, the clonidine dose could be
decreased by 50 percent if the infant had been stable. Heart rate and blood pressure were
monitored for rebound elevations, and then if there was no rebound tachycardia or
hypertension and withdrawal scores remained stable for 12 hours, the clonidine could be
discontinued altogether. (See Figure 2)
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All infants included in the study were treated at YNHH using the aforementioned
standard treatment protocols. Withdrawal symptoms were monitored by trained pediatric
nursing staff using a modified Finnegan neonatal abstinence scoring algorithm every
eight hours (Appendix A). The Finnegan scoring algorithm is a clinical tool used to
measure the severity of neonatal withdrawal. Twenty signs and symptoms most often
observed with neonatal withdrawal are ranked from one to five, with one being mild and
five being severe. These scores are then summed to give a total score that aims to
quantify the severity of withdrawal. (31)
Based on treatment for NAS, infants were divided into two groups: morphine
alone or morphine and clonidine. Infants who failed clonidine due to bradycardia or
hypotension were included in the morphine group. Continuous data was analyzed using
the Mann-Whitney U test due to the non-normal distribution of data and small sample
size. Adjustment for potential confounding factors was made using a multivariate
regression analysis. For descriptive statistics, means and standard deviations were
reported for normally distributed data, and medians and interquartile ranges for nonnormally distributed data. Continuous variables were analyzed using independentsamples t-test for between groups comparisons with equal variances not assumed. All
tests were two-tailed, and statistical significance was defined as a P value < 0.05. All
data were analyzed using SPSS version 18.0.
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Figure 1. NAS Treatment Algorithm for Diluted Oral Morphine Sulfate
Modified Finnegan Score Q8 hrs
Score ≥ 24 in 24 hours

Score ≤ 24 in 24 hours

Initiate Morphine Rx
0.08-0.12 mg/kg/dose Q3-4 hrs

Supportive Care and Assessment
with Score Q8 hrs

NAS Not Controlled
( Scores ≥ 10 in 8 hrs)

NAS Controlled
(Scores ≤ 10 in 8 hrs)

Increase Morphine Dose
0.04 mg/dose Q8 hrs
Until Sx Controlled
or Max Dose of 0.4 mg/dose

Sx Controlled for 2-3 Days
Wean by 10% of Max Morphine Dose
Q 1-3 Days

Sx Not Controlled
Reescalate to
Last Stable Morphine Dose

Discontinue Morphine
at 0.06mg/dose
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Results
One hundred and ninety four infants were identified by CPT code for NAS during
the study period. Of those, 77 were ineligible: eight transferred to other hospitals, eight
had NAS due to postnatal exposure to opiates, eleven had NAS but did not require
treatment, and 50 were less than 36 weeks gestation. One hundred and seventeen infants
met the inclusion criteria and were included in the analysis.
Both groups were similar with regard to infant demographic factors. There were
no significant differences in birth weight, gestational age, gender, mode of delivery,
Apgar scores at one and five minutes, type of feeding, or maximum diluted oral morphine
sulfate dose. Descriptive statistics and p values for these variables are listed in Table A.
All infants included in the study were exposed in utero to opioids, heroin,
methadone, or a combination of these. Fifty-nine were treated with morphine, and fiftyeight were treated with morphine and clonidine. The mean number of days of treatment
for the morphine group was 25.14 days (SD 12.738). The mean number of days of
treatment for the morphine and clonidine group was 19.57 days (SD 9.896). MannWhitney U rank sum test found the difference between these two groups to be significant
(p<0.05). (See Figure 3)
The ten subjects who failed treatment with clonidine due to bradycardia were
included in the morphine group. We did, however, do additional analyses with these
subjects included in the morphine and clonidine group to assess whether or not an
intention to treat design would be necessary. The results remained statistically significant
when a Mann-Whitney U rank sum test was done (p<0.05).
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Unstandardized β coefficients and 95% confidence intervals computed by linear
regression are as described in Table B. Additionally, there was no significant difference
in the maximum dose of morphine in either the morphine treatment group or the
morphine and clonidine treatment group (P=0.410).

Characteristics

Morphine

Morphine/Clonidine P Value

Treatment Group Treatment Group
N=117

59 (50.4%)

58 (49.6%)

Gestational Age

38.8 (SD 1.31)

38.78 (SD 1.64)

0.843

Birth Weight

2954 (SD 441.32)

3117.6 (SD 662.57)

0.120

Male Gender

31 (52.5%)

25 (43.1%)

0.311

Apgar at 1 minute

8.52 (SD 0.8)

8.44 (SD 1.25)

0.690

Apgar at 5 minutes

8.91 (SD 0.28)

8.81 (SD 0.58)

0.215

-Breastfeeding

1 (1.7%)

6 (10.3%)

0.111

-Formula

52 (88.1%)

46 (79.3%)

-Both

5 (8.5%)

4 (6.9%)

-Unknown

0 (0%)

2 (3.4%)

0.12 (SD 0.079)

0.14 (SD 0.167)

Type of Feeding

Max Morphine Dose

0.389

(mg/kg/dose)
Table A. Descriptive Characteristics and Comparisons Between Treatment Groups.
Values in parentheses represent percentages for categorical data. Independent Samples
T-test with equal variances not assumed was used.
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Factor

β Coefficient

95% Confidence

P Value

(Unstandardized)

Interval

Clonidine

-4.733

-9.09 to -0.367

0.034

Birth weight (Grams)

-0.001

-0.006 to 0.004

0.710

Gestational Age

1.576

-0.071 to 3.224

0.061

Feeding

-2.194

-6.408 to 2.020

0.304

(Breastfeeding vs.
Formula)
Table B. Factors Associated with Duration of Treatment in Infants Treated for NAS as
Described by Regression Analysis. Vaginal delivery (VD). Cesarean Section (C/S).
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Figure 3. Duration of treatment in infants treated with diluted oral morphine sulfate or
diluted oral morphine sulfate and diluted oral clonidine hydrochloride. Infants treated for
NAS with morphine alone had a median duration of treatment of 22 (IQR: 13) and those
with morphine and clonidine had a median duration of treatment of 16 (IQR: 13). These
differences were statistically significant (p=0.011, Mann-Whitney U)
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Discussion
Neonatal abstinence has been described and studied at length, yet the body of
literature regarding its assessment and treatment has yielded conflicting and somewhat
confusing results. As a result, clinical assessment and treatment of NAS varies widely.
(11, 12) Several classes of drugs including opioids, benzodiazepines, barbiturates, and
phenothiazines, have been studied and used alone or in combination for the treatment of
NAS. (34, 52)
Clonidine, which had previously been used successfully in older children and
adults for treatment of opioid withdrawal, has more recently been found to be useful in
the treatment of infants with NAS. (43-51) Our finding that treatment with clonidine and
morphine ameliorated symptoms of NAS and led to detoxification of infants more rapidly
than treatment with morphine alone further supports the data that clonidine is an
appropriate choice for the treatment of NAS when used as an adjunct to opioid therapy.
Clonidine is a desirable pharmacologic agent to use in the treatment of NAS
because it is neither a sedative nor an opioid. By acting centrally on α-2-adrenergic
receptors and inhibiting sympathetic outflow, clonidine works in parallel systems in the
same neurons as opioids. (34, 41, 42) Additionally, clonidine is well absorbed after oral
administration, and it is readily distributed in the central nervous system due to its lipid
solubility. (53)
Clonidine, however, is not without side effects. The more common side effects of
clonidine include hypotension, rebound hypertension, atrioventricular block, and
bradycardia. In our study ten subjects failed treatment with clonidine due to bradycardia.
Although rebound hypertension was not one of the data points we chose to specifically
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examine, none of the infants treated with clonidine had rebound hypertension. There
were also no incidences of rebound symptoms of NAS as seen in the Agthe et al. study.
(51) This could be due, in part, to the stepwise reduction of clonidine over 48 hours, as
well as weaning morphine completely before decreasing and subsequently discontinuing
clonidine as part of our standard treatment protocol for NAS at YNHH.
The use of clonidine as an adjunct to opioid treatment for infants with moderate to
severe NAS has larger social and economic implications. (54) Illicit drug use, and more
specifically opioid use, remains a significant social problem in the United States. (1-8)
Infants born with NAS require increased care including NICU observation, protracted
treatment courses, prolonged postnatal hospital stays, and often extensive social work
services while in the hospital. This increased need for and use of resources is also not
without impact on cost. A study done by Dryden et al. investigated the factors associated
with the development of NAS and assessed the implications for healthcare resources of
infants with prenatal exposure to illicit substances. They found that 48.4 percent of
infants born to women on methadone maintenance were admitted to the NICU. Infants
born to drug-misusing mothers represented 2.9 percent of hospital births, but they
occupied 18.2 percent of the total NICU spots for the period of the study. Furthermore,
almost all women in the study were assigned a social worker during their pregnancy, and
all families were assessed by the social work department prior to discharge from the
hospital. (54) Thus, finding a treatment regimen that decreases the amount and duration
of treatment for NAS could potentially alleviate at least some of the impact infants with
prenatal exposure to illicit substances has on healthcare resources.
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The study by Agthe et al. suggested a decreased need for opioids with the
addition of clonidine for the treatment of opioid withdrawal. (51) Our analysis found no
difference between the maximum doses of morphine required to control symptoms of
NAS in either treatment group (p > 0.05). Our study looked retrospectively at infants
treated over a six year period of time, and there was substantial variability in the
attending physicians treating the infants and the pediatric nursing staff assessing the
infants over that time period. This variability could have led to differences in scoring and
treating NAS that impacted the overall quality of our data. Given the limitations of our
study design as well as the paucity of data regarding the use of clonidine as an adjunct to
opioid therapy for neonatal withdrawal, additional studies designed to specifically look at
dosing requirements of opioids are needed to further clarify this. Additionally, not all
opioids have the exact same mechanism of action in the brain, so even with the guidelines
and recommendations that specify the use of opioids for NAS, randomized controlled
trials looking at different opioid therapies with or without clonidine also need to be done.
All infants included in our study were exposed in utero to opioids, mainly heroin
and/or methadone. This was confirmed by either maternal history as recorded in the
medical record or toxicology studies if results were available in the medical record.
Overall, doses of methadone that the mothers were taking at the time of delivery as
reported in the medical records of their infants, ranged from 15mg to 195mg.
Additionally, some of the women on methadone maintenance also had urine toxicology
studies or their infants had urine toxicology studies that were positive for substances
other than methadone, including but not limited to other opioids, cocaine and
barbiturates. Due to the limitations of our chart review and the quality of data available

26
for the maternal history of drug use, data obtained regarding amounts of methadone and
polydrug exposure was not subject to statistical analysis. There are studies to suggest
that maternal self-report alone can be unreliable and often under-reports the extent of in
utero exposure an infant has had, which is consistent with the small amount of data that
we were able to collect during our review. (19, 20) An important thing to note, however,
is that the subject population included in our study is heterogeneous with respect to
prenatal exposures. Although having a subject population that is heterogeneous in
prenatal exposure to illicit and prescribed substances complicates the characterization,
treatment, and response to treatment of infants with NAS, it is more representative of the
true patient populations that physicians are treating on a daily basis.
In addition to duration of treatment and maximum dose of morphine required to
ameliorate symptoms of NAS, we secondarily examined birth weight, gestational age,
gender, mode of delivery, Apgar scores at one and five minutes, and type of feeding.
None of these additional factors were found to have a statistically significant relationship
to the duration of treatment in either group. We also examined race, but 33 out of 117
subjects (28 percent) did not have this data available in their paper medical record, and
thus due to the large portion of missing data, this was not included in our analysis.
Although we did not find a significant relationship between duration of treatment
and gestational age, this is consistent with what we would expect given that gestational
age was one of the factors that we controlled for in our study design. Gestational age of
36 weeks or greater was chosen because there is some data that suggests that preterm
infants have a different neonatal course than infants born at term. (55, 56) One
retrospective cohort study looking at 53 preterm and 66 term infants with similar in utero
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exposure to methadone and other illicit substances found that preterm infants required
lower doses of opioid and shorter courses of treatment to control symptoms of NAS. (55)
Possible explanations for this differential course of NAS have been suggested and include
the relative maturity or immaturity of the central nervous system in premature infants, or
simply a decrease in length of in utero exposure of infants leading to a less severe clinical
course.
Additionally, we did not see a significant impact on duration of treatment with
mothers who breastfed. This could be in part due to the small numbers of mothers in our
study population who breastfed. Only one mother (1.7 percent) in the morphine group
breastfed exclusively, and five mothers (8.5 percent) supplemented breastfeeding with
formula. Six mothers (10.3 percent) in the morphine/clonidine group exclusively
breastfed, and four mothers (6.9 percent) supplemented breastfeeding with formula. The
low numbers of mothers who breastfeed in this population could be due in part to the
almost immediate separation of the mother and infant as the infant is taken to the NICU
for observation and possible treatment initiation. Another reason could be the often
complicated social situations of this patient population and not infrequent need for
placement of the infants in foster care or in the care of a relative other than the mother.
Studies have been done that look specifically at the impact of breastfeeding on the
severity of NAS and the duration of treatment of NAS. (54, 57, 58) One study by AbdelLatif et al. found that breast milk intake was associated with reduction in severity of NAS
and need for pharmacologic intervention regardless of gestational age or type of drug
exposure. (57). Moreover, breastfeeding in mothers on methadone maintenance has been
shown to be both beneficial and safe. (58).

28
Although our data did show a significant decrease in the duration of treatment for
infants treated with both morphine and clonidine, our study was limited by design and
sample size. Our data was limited to the information recorded in the medical records we
reviewed which was varied. Not all subjects had urine toxicology studies, and maternal
histories were limited to what was recorded at the time of delivery or obtained in the
history from the mother. Race was often not recorded in the paper medical records, but
could be found on result reports for the newborn screening test.
The study period of January 2003 to December 2009 was chosen specifically to
capture both infants treated with morphine alone which was the standard treatment
protocol at YNHH prior to 2006, and infants treated with both morphine and clonidine as
was the standard treatment protocol from 2006 to the present. The study period spans six
years. This was necessary in the design of the study to capture the desired data, however,
it increases the potential for increased variability and less consistency in the data.
Specifically, within the six years, the standard treatment protocol changed significantly,
resident and attending physicians changed, and medical records changed from paper to
electronic. Although there is increased potential for variability, the modified Finnegan
scoring algorithm has remained the same, and the treatment protocol with morphine has
also remained the same.
This retrospective medical record review supports the small but growing body of
literature supporting safety and efficacy of clonidine for opiate detoxification in infants
exposed in utero to opioids. Additional studies are indicated to look at long-term safety
of clonidine, and randomized controlled trials are needed to further characterize the use
of clonidine with different opioids.
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